Drug-induced long QT syndrome: molecular mechanisms for congenital and acquired QT prolongation

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 3, 2007, Pages 159-163

  Mason, Pamela K ^a   Mounsey, J Paul ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF NORTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; ASTEMIZOLE; CHLORPROMAZINE; CISAPRIDE; DISOPYRAMIDE; ERYTHROMYCIN; FLUCONAZOLE; GASTROINTESTINAL AGENT; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; METHADONE; MOXIFLOXACIN; NARCOTIC AGENT; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; POTASSIUM CHANNEL; PROCAINAMIDE; QUINIDINE; RANOLAZINE; SODIUM CHANNEL; TERFENADINE; THIORIDAZINE; UNINDEXED DRUG;

ARRHYTHMOGENESIS; BRADYCARDIA; CEREBROVASCULAR DISEASE; DRUG APPROVAL; ELECTROCARDIOGRAM; ELECTROLYTE DISTURBANCE; GENE MUTATION; GENETIC ASSOCIATION; HEART MUSCLE POTENTIAL; HEART VENTRICLE TACHYCARDIA; HUMAN; IN VITRO STUDY; ISOLATED HEART; LABORATORY TEST; LONG QT SYNDROME; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NONHUMAN; QT PROLONGATION; RADIOASSAY; REVIEW; TORSADE DES POINTES;

EID: 47049097494     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2008.04.003     Document Type: Review

References (28)

1. Modell S.M., and Lehmann M.H. The long QT syndrome family of cardiac ion channelopathies: a HuGE review. Genet. Med. 8 (2006) 143-155
2. Camm A.J., et al. Congenital and acquired long QT syndrome. Eur. Heart J. 21 (2000) 1232-1237
3. Ackerman M.J. Molecular basis of congenital and acquired long QT syndromes. J. Electrocardiol. 37 (2004) S1-S6
4. Vohra J. Drug-induced prolonged repolarisation (acquired long QT syndrome) arrhythmias. Heart Lung Circ. 12 (2003) S85-S89
5. Lehtonen A., et al. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de points. Heart Rhythm 4 (2007) 603-607
6. Roden D.M. Long QT syndrome: reduced repolarization reserve and the genetic link. J. Intern. Med. 259 (2006) 59-69
7. Shah M., et al. Molecular basis of arrhythmias. Circulation 112 (2005) 2517-2529
8. Roden D.M., and Temple R. The US food and drug administration cardiorenal advisory panel and the drug approval process. Circulation 111 (2005) 1697-1702
9. Roden D.M. An underrecognized challenge in evaluating postmarketing drug safety. Circulation 111 (2005) 246-248
10. Schram G., et al. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ. Res. 90 (2002) 939-950
11. Priori S.G., et al. A recessive variant of the Romano-Ward long QT syndrome?. Circulation 97 (1998) 2420-2425
12. Schulze-Bahr E., et al. KCNE1 mutation cause Jervell and Lange-Nielsen syndrome. Nat. Genet. 17 (1997) 267-268
13. Marban E. Cardiac channelopathies. Nature 451 (2002) 213-218
14. Roden D.M. Taking the 'idio' out of idiosyncratic. Predicting torsades de pointes. PACE 21 (1998) 1029-1034
15. Saenen, J.B. et al. A single hERG mutation underlying a spectrum of acquired and congenital long QT syndrome phenotypes. J. Mol. Cell. Cardiol. 43, 63-72
16. Roberts R. Genomics and cardiac arrhythmias. J. Am. Coll. Cardiol. 47 (2006) 9-21
17. Redfern W.S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58 (2003) 32-45
18. Roden D.M., and Viswanathan P.C. Genetics of acquired long QT syndrome. J. Clin. Invest. 115 (2005) 2025-2032
19. Kamiya K. Molecular determinants of hERG channel block. Mol. Pharmacol. 69 (2006) 1709-1716
20. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2005) E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.fda.gov/cder/guidance/index.htm
21. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2004) S7B The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. http://www.fda.gov/cder/guidance/index.htm
22. Shah R.R., and Hondeghem L.M. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2 (2005) 758-772
23. Hammond T.G., and Pollard C.E. Use of in vitro methods to predict QT prolongation. Toxicol. Appl. Pharmacol. 207 (2005) S446-S450
24. Valentin J.-P., et al. Review of the predictive value of the Langendorff heart model (screenit system) in assessing the proarrhythmic potential of drugs. J. Pharmacol. Toxicol. Meth. 49 (2004) 171-181
25. Finlayson K., et al. Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur. J. Pharmacol. 500 (2004) 129-142
26. De Ponti F., et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes. Drug Saf. 25 (2002) 263-286
27. Carlsson L. In vitro and in vivo models for testing arrhythmogenesis in drugs. J. Intern. Med. 259 (2006) 70-80
28. Antzelevitch C. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110 (2004) 904-910